Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Integrated NGS assays for genomic profiling of haematological malignancies
Univ8 Genomics is a Belfast-based genomics diagnostics company developing targeted next-generation sequencing assays for the integrated clinical characterisation of haematological malignancies. Its assays enable simultaneous detection of clonal rearrangements, chromosomal translocations, copy number alterations and…
AI-driven T-cell receptor discovery platform for solid tumour immunotherapies
Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell…
Europe's largest biomedical discovery institute researching the biology of disease
The Francis Crick Institute is a biomedical discovery institute researching the biology underlying human health and disease. The Institute studies biology from molecules to entire organisms, translating discoveries into new ways to treat illnesses including cancer, heart disease and neurodegenerative conditions.…
CreaTap antibody engineering for improved solid tumour penetration
Creasallis is a biotechnology company developing antibody engineering technologies intended to improve drug delivery into solid tumours. Its patented CreaTap platform modifies therapeutic antibodies to promote deeper penetration into tumour tissue. The approach is under development for monoclonal antibodies,…
Lentiviral gene therapy developer for tumours and rare diseases
Santo Therapeutics develops in vivo lentiviral gene therapies for cancer and rare genetic disorders. Its proprietary vector platform supports programmes including ST002, an NF2 gene-replacement therapy for NF2-related schwannomatosis. The company announced the start of an investigator-initiated clinical trial of ST002…
Gene therapy platform targeting paediatric solid tumours
Kindling Bio is a biotechnology company developing a gene therapy platform designed specifically for childhood cancers. The platform engineers a biological signal that renders paediatric solid tumours visible to the immune system, enabling immune-mediated destruction across multiple tumour types from a single…
Deep learning platform for small molecule drug discovery
CHARM Therapeutics is a clinical-stage biotechnology company applying 3D deep learning to small molecule drug discovery. Its proprietary platform uses protein-ligand co-folding algorithms to predict binding interactions and identify candidates against difficult-to-drug targets. CHARM's pipeline focuses primarily on…
T cell-engaging multispecific antibody fragments for solid tumours
Crescendo Biologics is a clinical-stage biopharmaceutical company developing multispecific therapeutics based on fully human single-domain antibody fragments engineered for enhanced tumour penetration and selective T cell activation within the tumour microenvironment. Its lead programme is in Phase 1b clinical trials…
ML-enabled nanoparticle delivery platform for targeted therapeutics
Vector Bioscience is a University of Cambridge spin-out developing a machine learning-enabled drug delivery platform based on metal-organic framework nanoparticles. The technology provides cargo-agnostic, targeted delivery of oligonucleotides and small molecules with controlled release, initially focused on…
Preclinical CRO delivering integrated drug discovery and development services
Selvita is a contract research organisation providing integrated drug discovery and development services to pharmaceutical and biotechnology companies. The company supports projects from target validation through preclinical candidate nomination, with expertise in medicinal chemistry, pharmacology, DMPK and protein…
Proteomics and AI liquid biopsy for early lung cancer detection
Oxford Cancer Analytics is a biotechnology company developing blood-based diagnostic tests for early cancer detection using high-throughput circulating proteome analysis and machine learning. Its platform identifies protein biomarker signatures from blood samples to support clinical decision-making in lung disease,…
Translational CRO offering oncology and women's health assay services
Inaphaea BioLabs is a translational contract research organisation based at MediCity Nottingham, offering cell-based assays and patient-derived cell (PDC) models to support early-stage drug discovery and preclinical development. The company specialises in oncology and women's health, providing biochemical and…
Tumour-activated peptide drug conjugates for targeted oncology
Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour microenvironment. The company's delivery approach uses a short engineered peptide that masks the active payload until it is cleaved by…
Blood-based circulating tumour DNA tests for cancer
Inivata is a liquid biopsy company developing molecular tests for cancer using circulating tumour DNA from blood samples. Its sequencing-based assays identify tumour-associated genetic changes and have been used to investigate residual disease, recurrence and treatment response. The technology supports molecular…
Full-service clinical and commercial solutions across the drug development lifecycle
Syneos Health is a global biopharmaceutical solutions organisation providing integrated clinical and commercial services to pharmaceutical, biotechnology and medical device companies. Its Clinical Solutions offering spans Phase I to IV development, including clinical monitoring, patient recruitment, data management…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
AI-guided synthetic lethality drug discovery for oncology
Evariste is a drug discovery company developing small-molecule inhibitors of synthetic lethal targets in cancer. Its computational platform combines machine learning, multimodal biological data and molecular modelling to identify therapeutic targets, design candidate compounds and prioritise laboratory testing. The…
Specialist oncology CRO for early and late phase clinical trials
Theradex (Europe) Limited is the European arm of Theradex Oncology, a US-founded CRO with over 40 years specialising in oncology clinical development. The company provides full-service clinical trial management for pharma and biotech sponsors across early and late phase studies, with expertise in oncology,…
In vivo lentiviral CAR/TCR cell therapy platform for ovarian cancer
Akimbo Bio is an early-stage biotechnology company developing next-generation in vivo lentiviral vector technology for cell therapy. Its lead platform carries a dual CAR/TCR payload designed for direct in vivo delivery, with an initial focus on ovarian cancer. The technology uses intelligent receptor crosstalk, in…
Targeted nanoparticles for in vivo CAR-T and gene delivery
Deliver Biosciences is a biotechnology company developing targeted nanoparticle vectors for in vivo cell and gene therapies. Its delivery platform transports genetic payloads, including DNA and mRNA, into selected cell types using programmable targeting components. Its lead programme aims to engineer T cells inside…